BioMarin Nederland B.V.

BioMarin Nederland B.V., a biotechnology company, engages in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders. Its products focus on the treatment of neuromuscular and neurodegenerative disorders, including duchenne muscular dystrophy (DMD), myotonic dystrophy, and huntington’s diseases. The company develops drisapersen, which is in Phase III studies to restore dystrophin expression and enhancing muscle condition; PRO044 that is in Phase I/II studies to address a separate sub-population of DMD patients; and PRO045, PRO053, PRO052, and PRO055 to address other distinct sub-populations of DMD patients. It also develops PRO135 that is in preclinical trials for myotonic dystrophy; PRO289, which is in preclinical trials for treating huntington’s diseases; and PROSPECT to address mutations in the exon. BioMarin Nederland B.V. was formerly known as Prosensa Therapeutics B.V. The company was incorporated in 1997 and is headquartered in Leiden, the Netherlands. As of January 29, 2015, BioMarin Nederland B.V. operates as a subsidiary of BioMarin Leiden Holding BV.